Copenhagen, Denmark Saturday, May 3, 2025, 12:00 Hrs [IST] ...

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation to Bavarian Nordic's ...

The Medicines and Healthcare products Regulatory Agency (MHRA) yesterday approved Vimkunya, a vaccine used to prevent disease caused by the chikungunya virus in people 12 years of age and older. The ...

VIMKUNYA is a single dose, prefilled, adjuvanted VLP recombinant protein vaccine for active immunization for the prevention ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has today (1 May 2025) approved a vaccine (Vimkunya) used to ...

Recommendations for the use of chikungunya vaccine were recently discussed at a meeting of the Advisory Committee on Immunization Practices.

French health authorities have suspended the use of Valneva’s chikungunya vaccine Ixchiq in adults aged 65 and older after ...

Models find no difference in all-cause death rates, 30-day hospital readmission, or length of stay before and after ...

A coalition of groups sent a letter to the HHS secretary outlining steps he should take to reduce antibiotic use in ...

As safety flags hang over Valneva’s chikungunya vaccine in the U.S. and beyond, French authorities are clamping down on the shot’s use in older adults. | France’s public health agency has temporarily ...

Valneva said it has been supplying Ixchiq to help the French government respond to a major outbreak of chikungunya in La ...